Overview

• Medifast Q3 revenue falls 36.2% yr/yr due to fewer active earning coaches

• Company reports Q3 net loss of $2.3 mln, compared to net income last year

• Medifast maintains strong balance sheet with $173.5 mln in cash, no debt

Outlook

• Company expects Q4 2025 revenue between $65 mln and $80 mln

• Company projects Q4 2025 diluted loss per share between $0.70 and $1.25

Result Drivers

• COACH DECLINE - Revenue decrease primarily driven by 35% drop in active earning OPTAVIA coaches

• GLP-1 IMPACT - Challenges in client acquisition due to acceptance of GLP-1 medications for weight loss

• STRATEGIC TRANSFORMATION - Co is shifting focus to metabolic health, aiming for larger market

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the food processing peer group is "buy."

• Wall Street's median 12-month price target for Medifast Inc is $15.00, about 19.9% above its October 31 closing price of $12.02

Press Release: ID:nBw4xsXfHa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)